Back to top
more

iTeos Therapeutics (ITOS)

(Delayed Data from NSDQ)

$10.80 USD

10.80
140,901

+0.20 (1.89%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $10.81 +0.01 (0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Strength Seen in iTeos Therapeutics, Inc. (ITOS): Can Its 7.4% Jump Turn into More Strength?

by Zacks Equity Research

iTeos Therapeutics, Inc. (ITOS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Wall Street Analysts Believe iTeos Therapeutics, Inc. (ITOS) Could Rally 243.43%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 243.4% upside potential for iTeos Therapeutics, Inc. (ITOS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does iTeos Therapeutics, Inc. (ITOS) Have the Potential to Rally 283.59% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 283.6% in iTeos Therapeutics, Inc. (ITOS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Here's Why iTeos Therapeutics, Inc. (ITOS) Could be Great Choice for a Bottom Fisher

by Zacks Equity Research

iTeos Therapeutics, Inc. (ITOS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Wall Street Analysts Predict a 304.26% Upside in iTeos Therapeutics, Inc. (ITOS): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for iTeos Therapeutics, Inc. (ITOS) points to a 304.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Viridian Therapeutics, Inc. (VRDN) Stock Jumps 5.2%: Will It Continue to Soar?

by Zacks Equity Research

Viridian Therapeutics, Inc. (VRDN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

iTeos Therapeutics, Inc. (ITOS) Stock Jumps 5.4%: Will It Continue to Soar?

by Zacks Equity Research

iTeos Therapeutics, Inc. (ITOS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Biotech Stocks Rally After Roche's (RHHBY) Accidental Data Leak

by Zacks Equity Research

Shares of several companies developing anti-TIGIT therapies rise after Roche (RHHBY) accidentally leaks encouraging late-stage study data.

Roche (RHHBY) Up on Upbeat Data From Combo Drug Cancer Study

by Zacks Equity Research

Roche's (RHHBY) stock jumps 4.3% on Wednesday after the company inadvertently publishes encouraging second interim analysis data from its combination drug study to treat cancer.

ITeos Therapeutics, Inc. (ITOS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 55.56% and 8.73%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Bluebird Bio (BLUE) Q1 Earnings Surpass Estimates

by Zacks Equity Research

Bluebird (BLUE) delivered earnings and revenue surprises of 138.89% and 89.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Dynavax Technologies (DVAX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -58.33% and 21.35%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ITeos Therapeutics, Inc. (ITOS) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 35.71% and 30.97%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -4.76% and 15.86%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ITeos Therapeutics, Inc. (ITOS) Lags Q3 Earnings and Revenue Estimates

by Zacks Equity Research

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of -57.14% and 53.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ITeos Therapeutics, Inc. (ITOS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

ITeos Therapeutics, Inc. (ITOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ITeos Therapeutics, Inc. (ITOS) Q2 Earnings and Revenues Lag Estimates

by Zacks Equity Research

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of -87.50% and 56.97%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Is BioNTech (BNTX) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

ITeos Therapeutics, Inc. (ITOS) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 127.50% and 140.95%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Roche (RHHBY) Phase III NSCLC Study Disappoints, Stock Down

by Zacks Equity Research

Roche (RHHBY) stock declines as the late-stage study evaluating tiragolumab plus Tecentriq fails to meet its co-primary endpoint of progression-free survival.

ITeos Therapeutics, Inc. (ITOS) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 278.29% and 181.44%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

5 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates

by Kinjel Shah

Let us take a look at some drug/biotech stocks, EVLO, GMDA, APLS, MRTX and ITOS, which are poised to beat on fourth-quarter earnings.

Why iTeos Therapeutics, Inc. (ITOS) Might be Well Poised for a Surge

by Zacks Equity Research

iTeos Therapeutics, Inc. (ITOS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Wall Street Analysts Believe iTeos Therapeutics, Inc. (ITOS) Could Rally 53%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 53.3% upside potential for iTeos Therapeutics, Inc. (ITOS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

ITeos Therapeutics, Inc. (ITOS) Lags Q3 Earnings and Revenue Estimates

by Zacks Equity Research

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of -62.42% and -68.38%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?